A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TAS5315 in chronic
spontaneous urticaria patients with an inadequate response to H1-antihistamines